Investors / Transhuman Capital
Transhuman Capital
Venture capital
Transhuman Capital is a venture firm established in 2014 that invests in therapeutics and related medical technologies. It partners with seed through crossover stage biotechnology companies.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsmedical technologyhard sciencelife sciences
Your fit with Transhuman Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsTranshuman Capital lists 6 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside AAIC Investment, Checkmate Capital and Chengwei Capital.
Counts come from funding rounds that name Transhuman Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 8th | 6 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| AAIC Investment | 1 |
| Checkmate Capital | 1 |
| Chengwei Capital | 1 |
| Commonweal Ventures | 1 |
| Enavate Sciences | 1 |
| Evolution VC Partners | 1 |
| HAX | 1 |
| HSG | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Transhuman Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Transhuman Capital| Date | Company | Stage |
|---|---|---|
| 16 Dec 2025 | Series A |
Round details for Transhuman Capital
Amounts, full round histories and every co-investor in Transhuman Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
6 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need. | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| Bond Biosciences discovers and develops non-absorbed oral therapeutics to prevent and treat ion-related human diseases | Healthcare & Biotech | Portfolio page | ||
| Cyana Therapeutics is a precision immuno-oncology company developing drugs to treat solid tumors. | Healthcare & Biotech | Portfolio page | ||
| Evecxia Therapeutics is developing novel proprietary drug delivery technologies that enable the therapeutic properties of 5-HTP to treat mental illnesses. | Healthcare & Biotech | Portfolio page | ||
| Roivant develops transformative medicines and technologies by building agile, focused companies | Healthcare & Biotech | Portfolio page | ||
| Sana Health develops an audio-visual device for neuropathic pain relief | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- transhumancapital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 16 Dec 2025
- Companies checked
- 6
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Transhuman Capital's profile as data
Pull Transhuman Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/transhumancapital.com
# also
GET /v1/firms/transhumancapital.com/portfolio
GET /v1/firms/transhumancapital.com/coinvestors
GET /v1/firms/transhumancapital.com/news